Liver Heat Decoction Combined With Entecavir For Endoretention Of Damp Heat Syndrome Clinical Study Of HBeAg Positive Chronic Hepatitis B

Objective:In view of the nucleoside/nucleotide analogues and interferon limitations in Chronic Hepatitis B during the treatment, some patients treated with entecavir has been unable to achieve e antigen seroconversion.So some patitents compliance decreased, even development of the diserse to liver cirrhosis, liver cancer. With the practice of TCM, We found that Traditional Chinese Medicine not only can protect the liver cells and prevent liver fibrosis,but also anti-virus and reduce the side effects related to antiviral drugs. To some extent, prevention of liver cancer has played a certain role. The purpose of this study is that finally achieves significant improvement of seroconversion of some patients e antigen and other related indicators by the entecavir and prescription of Traditional Chinese Medicine of organic combination.Methods:According to the simple random,48cases of HBeAg positive Chronic Hepatitis B patients, consistent with the Chinese Society of Hepatology and Infection against branch 2010 edition of "Guide" for prevention and treatment of Chronic Hepatitis B antiviral treatment of Chinese Medical Association, Entecavir treatment for more than a year, HBV-DNA achieved a partial response and some negative, but still positive e antigen this patients,We were randomly divided into experimental group and control group,24 cases in each group. The experimental group was given Entecavir and liver heat decotion (Artemisia20g,Porial5g,Large-headed atractylodes 10g,Skullcap9g,Turmeric 15g,Przewaquinone 15g,Citrus10g,Sophoral 5g,Panax notoginsenoside5g,Ginger10g and so on) treatment, The Control Group was given entercavir and polyethylene glycol(peg)interferon a-2a 180 micrograms of treatment for a year(weight is less than 50kg to 135 micrograms),The course is a year. We regularly studies in patients with liver and kidney function, Hepatitis B two pairs of semi quantitative, HBVDNA, AFP, liver fibrosis, liver and spleen in ElastPQ, blood routine, thyroid function, blood glucose, auto-immune indicators. At the same time, It related clinical symptoms scale analysis, We are adverse reactions that given appropriate symptomatic treatment of Western medicine during interferon therapy.Results:48 patients lost 8 cases, We actually observed 40 cases,22cases in the experimental group,18 cases in the control group, no significant differences in baseline characteristics between 2 groups. Through statistical tests, The experimental group and control group for comparison, in the biochemistry, liver function of two groups after treatment than before have improved, but liver function index of the experimental group improved significantly higher than the control group, there was significant difference (P<0.05);In the infectious immunology, two groups of HBeAg serum conversion rate were increased. While the control group of HBsAg serum conversion rate was higher than the experimental group, the experimental group compared before and after the treatment, HBeAg conversion rate after treatment was significantly higher than before (p<0.05);In the virology, the two groups after treatment of HBV-DNA overcast rate was significantly lower than before treatment, But between the two groups after treatment compared with no significant statistical difference(p>0.05);In the cellular immunity,Through48 weeks after treatment in both groups, the percentage of CD4+,CD8+and CD4+/CD8+in the experimental group was higher than the control group, there was statistical difference(p<0.05);In the oncology, although compared two groups of patients by value after treatment with AFP before treatment, no significant difference (p>0.05),but the experimental group decreased significantly than before treatment of AFP after treatment (p<0.05);In the liver fibrosis, according to the two groups before treatment and after treatment of serum hepatic fibrosis three indicators compared, the experimental group after treatment of liver fiber three indicators obviously improved than the control group, with statistical difference(p<0.05); In the imaging aspects, the control group compared to the experimental group in B ultrasonic to exceed ELASTPQ value after treatment, the experimental group could obviously improve ELASTPQ value, there was statistical significantly(p<0.05);In the clinical symptoms, such as chest pain, bitter mouth, anorexia, anorexia, abdominal distension etc, the control group compared with the experimental group, the experimental group had significantly improved, with significant difference (P<0.05).Conclusion:Entecavir combined liver heat Decoction not only can significantly improve the liver function, ease fibrosis index, improve the antiviral effect and treatment compliance, What’s more, It can reduce the symptoms of patients, ease the cost of treatment and slow disease progress. The experimental group was better than the control group, easily accepted by the patients.